Middle East and Africa Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Published Report
  • Jul 2019
  • MEA
  • 350 Pages
  • No of Tables: 89
  • No of Figures: 27

Middle East and Africa Anticoagulation Therapy Market By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (South Africa, Rest Of Middle East And Africa). – Industry Trends and Forecast to 2026

Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).

Middle East and Africa anticoagulation therapy market is projected to register a substantial CAGR in the forecast period 2019 to 2026.

Segmentation: Middle East and Africa Anticoagulation Therapy Market

Middle East and Africa anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.

  • On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
  • On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
  • On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
  • On the basis of route of administration, the market is segmented into oral and injectable
  • On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
  • On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
  • On the basis of type, the market is segmented into generics and branded
  • On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
  • On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

 Competitive Analysis: Middle East and Africa Anticoagulation Therapy Market

Some of the major players operating in the Middle East and Africa anticoagulation therapy market are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical(Group)Co., Ltd., Cipla Inc, Johnson & Johnson Services, Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc, Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.

Recent Development

  • In April 2018, Hikma Pharmaceuticals PLC has formed licensed agreement with Laboratorios Farmaceúticos Rovi SA for its enoxaparin biosimilar and in March Rovi received approval for Lovenox and Clexane (enoxaparin biosimilar) in 16 European counties market, Hikma got exclusive rights to distribute and market enoxaparin across its MENA markets as an outcome of agreement. The major focus of this agreement is to increase global market presense and to become a leader in the lowmolecular-weight heparin field.

Research Methodology: Middle East and Africa Anticoagulation Therapy Market

Primary Rependants:

Key Opinion Leaders (KOL’s): Manufacturers, Researchers, Distributors, Bakers and Food Industrialists.

Industry Participants: CEO’s, V.P.’s, Marketing/Product Managers, Market Intelligence Managers and National Sales Managers.


SKU-

TABLE 1 AGEING WORLD POPULATION

TABLE 2 POSTOPERATIVE PULMONARY EMBOLISM OR DEEP VEIN THROMBOSIS IN HIP AND KNEE SURGERIES, 2015

TABLE 3 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA DEEP VEIN THROMBOSIS (DVT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA PULMONARY EMBOLISM (PE) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA ARTERIAL THROMBOEMBOLISM (AT) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA STROKE IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA NOVEL ORAL ANTICOAGUALTANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA BIVALIRUDIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA DABIGATRAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA EDOXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA BETRIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA RIVAROXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA APIXABAN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA ENOXAPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA DALTEPARIN IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION , 2017-2026 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA ORAL IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA INJECTABLES IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA ONCOLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA RESPIRATORY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA NEPHROLOGY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA CNS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA PRE-SURGICAL PROCEDURES IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA POST-SURGICAL PROCEDURES IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA KIDNEY DIALYSIS IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA HEART VALVE REPLACEMENT IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA GENERICS IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA BRANDED IN MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA HOSPITALS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA CLINICS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA HOMECARE IN ANTICOAGULATION THERAPY MARKET,BY REGION, 2017-2026 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA OTHERS IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 56 RETAIL PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN ANTICOAGULATION THERAPY MARKET, BY REGION, 2017-2026 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY COUNTRY, 2017-2026 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 67 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 74 U.S. ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

TABLE 75 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 76 SOUTH AFRICA NOVEL ORAL ANTICOAGULANTS (NOAC) IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 77 SOUTH AFRICA HEPARIN IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 78 SOUTH AFRICA VITAMIN K ANTAGONISTS IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS, 2017-2026 (USD MILLION)

TABLE 79 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE, 2017-2026 (USD MILLION)

TABLE 80 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 81 SOUTH AFRICA INJECTABLE IN ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)

TABLE 82 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY THERPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 83 SOUTH AFRICA CARDIOVASCULAR DISEASES IN ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA, 2017-2026 (USD MILLION)

TABLE 84 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)

TABLE 85 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 86 SOUTH AFRICA BRANDED IN ANTICOAGULATION THERAPY MARKET, BY TYPE, 2017-2026 (USD MILLION)

TABLE 87 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY END USER, 2017-2026 (USD MILLION)

TABLE 88 SOUTH AFRICA ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)

TABLE 89 REST OF MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET, BY TREATMENT, 2017-2026 (USD MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions